Literature DB >> 30392479

High-risk psychotropic medications for US children with trauma sequelae.

E R Barnett1, M T Concepcion Zayas2.   

Abstract

Children exposed to trauma are predisposed to develop a number of mental health syndromes. They are prone to under-treatment with effective psychosocial interventions and over-treatment with high-risk psychotropic medications, especially polypharmacy and the use of antipsychotics for unapproved conditions. We review the evidence for psychosocial and pharmacological treatments for mental health problems associated with high exposure to childhood trauma - identifying those in foster care as an index group - and the frequency of high-risk pharmacological practices. We describe current efforts to reduce over-treatment of children with high-risk psychotropic medications and propose further recommendations to protect and provide effective care for these vulnerable children.

Entities:  

Keywords:  Child psychiatry; evidence-based psychiatry; psychotropic drugs; trauma

Mesh:

Substances:

Year:  2018        PMID: 30392479      PMCID: PMC6998973          DOI: 10.1017/S2045796018000616

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  37 in total

Review 1.  History of maltreatment and mental health problems in foster children: a review of the literature.

Authors:  Sylvia H Oswald; Katharina Heil; Lutz Goldbeck
Journal:  J Pediatr Psychol       Date:  2009-12-10

Review 2.  Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.

Authors:  Eugenia Chan; Jason M Fogler; Paul G Hammerness
Journal:  JAMA       Date:  2016-05-10       Impact factor: 56.272

3.  Practice parameter for the assessment and management of youth involved with the child welfare system.

Authors:  Terry Lee; George Fouras; Rachel Brown
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-06       Impact factor: 8.829

4.  The Impact of a State Medicaid Peer-Review Authorization Program on Pediatric Use of Antipsychotic Medications.

Authors:  Dinci Pennap; Mehmet Burcu; Daniel J Safer; Julie Magno Zito
Journal:  Psychiatr Serv       Date:  2017-11-15       Impact factor: 3.084

Review 5.  Psychotropic medications for highly vulnerable children.

Authors:  Jennifer L McLaren; Erin R Barnett; Milangel T Concepcion Zayas; Jonathan Lichtenstein; Stephanie C Acquilano; Lisa M Schwartz; Steven Woloshin; Robert E Drake
Journal:  Expert Opin Pharmacother       Date:  2018-03-29       Impact factor: 3.889

6.  Antipsychotic treatment among youth in foster care.

Authors:  Susan Dosreis; Yesel Yoon; David M Rubin; Mark A Riddle; Elizabeth Noll; Aileen Rothbard
Journal:  Pediatrics       Date:  2011-11-21       Impact factor: 7.124

7.  Psychiatric problems and trauma exposure in nondetained delinquent and nondelinquent adolescents.

Authors:  Zachary W Adams; Michael R McCart; Kristyn Zajac; Carla Kmett Danielson; Genelle K Sawyer; Benjamin E Saunders; Dean G Kilpatrick
Journal:  J Clin Child Adolesc Psychol       Date:  2012-12-13

8.  Monitoring of Patients on Second-Generation Antipsychotics: A National Survey of Child Psychiatrists.

Authors:  Jennifer L McLaren; Mary F Brunette; Gregory J McHugo; Robert E Drake; William B Daviss
Journal:  Psychiatr Serv       Date:  2017-04-17       Impact factor: 3.084

9.  Substance Use and Substance Use Disorders as Foster Youth Transition to Adulthood.

Authors:  Sarah Carter Narendorf; J Curtis McMillen
Journal:  Child Youth Serv Rev       Date:  2010-01-01

Review 10.  Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs.

Authors:  Jon Jureidini; Anne Tonkin; Elsa Jureidini
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

View more
  1 in total

1.  Inter-class Concomitant Pharmacotherapy in Medicaid-Insured Youth Receiving Psychiatric Residential Treatment.

Authors:  Gail A Edelsohn; Kemal Eren; Meghna Parthasarathy; Neal D Ryan; Amy Herschell
Journal:  Front Psychiatry       Date:  2021-05-20       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.